Abstract

This is an update to the EtR framework for the following policy question:
Should individuals ages 5–11 years receive a Pfizer-BioNTech COVID-19 vaccine booster dose at least 5 months after completion of the primary series, based on the balance of benefits and risks?

Presented during the meeting of May 19th 2022.

  • Background paper
  • Americas
  • United States of America
  • children
  • COVID-19